Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

DelveInsight's Gastroesophageal Reflux Disease Market Insights report includes a comprehensive understanding of current treatment practices, gastroesophageal reflux disease emerging drugs, market ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-T) from The Globe and Mail including charting and trades.

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis ...

An endoscopy can diagnose eosinophilic esophagitis (EoE), but it’s also an important tool for monitoring how well medical therapy is working — especially when you switch treatment types. “Typically an ...

Eosinophilic esophagitis (EoE) is no longer a rarity in European clinics. Diagnosed increasingly over the past three decades, EoE is commonly managed with pharmacotherapy, elimination diets, and, when ...

“In EoE, PPIs are used for anti-inflammatory properties rather than acid suppression,” says Alex Koral, MD, a gastroenterologist and an associate professor of pediatric gastroenterology at Yale School ...

AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test ® (EST), marking a ...

On Monday, Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) reported data from patients in Cohort nine of the dose escalation portion of the RESOLVE trial in Eosinophilic Esophagitis (EoE) patients, the ...

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. VICTORIA, ...

Patients with eosinophilic esophagitis (EoE) often describe the condition as painful, disruptive and frightening. The rare chronic disease causes inflammation of the esophagus, leading to abdominal ...

At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI All Cohorts followed to 9 months have maintained clinically ...